ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7

QR Code

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7

Emerging SARS-CoV-2 variants raise concerns about vaccine effectiveness. Here, the authors show that the ChAdOx1 nCoV-19 (AZD1222) vaccine protects Syrian hamsters from pulmonary infection and disease after infection with SARS-CoV-2 B.1.351 or B.1.1.7 variants.

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Robert J. Fischer, Neeltje van Doremalen, Danielle R. Adney, Claude Kwe Yinda, Julia R. Port, Myndi G. Holbrook, Jonathan E. Schulz, Brandi N. Williamson, Tina Thomas, Kent Barbian, Sarah L. Anzick, Stacy Ricklefs, Brian J. Smith, Dan Long, Craig Martens, Greg Saturday, Emmie de Wit, Sarah C. Gilbert, Teresa Lambe, Vincent J. Munster
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/cd521c32186f4059b6298768dcc0d51a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
par: Glenn A. Marsh, et autres
Publié: (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
par: Sue Ann Costa Clemens, et autres
Publié: (2021)

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
par: Donata Hoffmann, et autres
Publié: (2021)

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
par: Michiko Asano, et autres
Publié: (2022)

Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021.
par: Lamprini Veneti, et autres
Publié: (2021)

Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
par: Maryam Hojjat Jodaylami, et autres
Publié: (2021)

SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains
par: Peter Radvak, et autres
Publié: (2021)

Author Correction: Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
par: Maryam Hojjat Jodaylami, et autres
Publié: (2021)

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <italic toggle="yes">In Vivo</italic> in a Mouse Model in a Neutralization-Dependent Manner
par: Fatima Amanat, et autres
Publié: (2021)

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
par: Chandima Jeewandara, et autres
Publié: (2021)

SARS-CoV-2 B.1.1.7 Variant Infection in Malayan Tigers, Virginia, USA
par: Patrick K. Mitchell, et autres
Publié: (2021)

Emergence of B.1.1.318 SARS-CoV-2 viral lineage and high incidence of alpha B.1.1.7 variant of concern in the Republic of Gabon
par: Gédéon Prince Manouana, et autres
Publié: (2022)

Rapid screening for SARS-CoV-2 VOC-Alpha (202012/01, B.1.1.7) using the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay
par: Nicla Giovacchini, et autres
Publié: (2021)

Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions
par: Sang Won Lee, et autres
Publié: (2021)

SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters
par: Julia R. Port, et autres
Publié: (2021)

Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
par: Anthony P. West, et autres
Publié: (2021)

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
par: Shepherd R. Singer, M.D., et autres
Publié: (2021)

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
par: Shuai Xia, et autres
Publié: (2021)

The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City
par: Alberto Cedro-Tanda, et autres
Publié: (2021)

Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy
par: Daniela Loconsole, et autres
Publié: (2021)

Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium
par: Franck Touret, et autres
Publié: (2021)

Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines
par: William M. de Souza, et autres
Publié: (2021)

Real-Time Projections of SARS-CoV-2 B.1.1.7 Variant in a University Setting, Texas, USA
par: Kaitlyn E. Johnson, et autres
Publié: (2021)

Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide
par: Yeonju Kim, et autres
Publié: (2021)

Emergence of B.1.524(G) SARS-CoV-2 in Malaysia during the third COVID-19 epidemic wave
par: Kim-Kee Tan, et autres
Publié: (2021)

Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions
par: Gytis Dudas, et autres
Publié: (2021)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
par: Yuko Sakai-Tagawa, et autres
Publié: (2021)

SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study
par: Judith Breuer, et autres
Publié: (2021)

The interaction of the bioinsecticide PA1b (Pea Albumin 1 subunit b) with the insect V-ATPase triggers apoptosis
par: Vanessa Eyraud, et autres
Publié: (2017)

Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021
par: Thomas Wilton, et autres
Publié: (2021)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
par: Hao Zhou, et autres
Publié: (2021)

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
par: Teresa Lambe, et autres
Publié: (2021)

I(nsp1)ecting SARS-CoV-2–ribosome interactions
par: Matthieu Simeoni, et autres
Publié: (2021)

A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1
par: Kun-Wei Chan, et autres
Publié: (2021)

Editorial (V.1 N.1)
par: Marianela Costa Figueiredo Rodrigues da Silva
Publié: (2021)

Acta N°1222
par: Banco Central de Chile
Publié: (2021)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
par: Moghbeli,Meysam, et autres
Publié: (2019)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
par: Kenji Maeda, et autres
Publié: (2021)

Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1
par: Mustafa Sait Gönen, et autres
Publié: (2021)

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
par: Haijun Tang, et autres
Publié: (2021)